• Explore /
  • Poster
  • / CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.

Abstract Video & Slides Poster

Authors

null

Yi Lin

Mayo Clinic, Rochester, MN

Yi Lin , Thomas G. Martin , Saad Zafar Usmani , Jesus G. Berdeja , Andrzej J. Jakubowiak , Mounzer E. Agha , Adam D. Cohen , Abhinav Deol , Myo Htut , Alexander M. Lesokhin , Nikhil C. Munshi , Elizabeth O'Donnell , Carolyn Chang Jackson , Tzu-min Yeh , Arnob Banerjee , Enrique Zudaire , Deepu Madduri , Christopher delCorral , Lida Bubuteishvili-Pacaud , Sundar Jagannath

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for Plasma Cell Disorders

Clinical Trial Registration Number

NCT03548207

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8009)

DOI

10.1200/JCO.2023.41.16_suppl.8009

Abstract #

8009

Poster Bd #

1

Abstract Disclosures

Similar Posters

First Author: Saad Zafar Usmani

First Author: Doris K. Hansen

First Author: Karnav Modi

First Author: Thomas G. Martin